PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today the issuance of the first patent for the composition of matter and formulation of TIVORBEX™ (indomethacin) capsules by the United States Patent and Trademark Office (USPTO). The company also received a second patent for ZORVOLEX® (diclofenac) capsules covering its manufacturing method. ZORVOLEX and TIVORBEX were approved in October 2013 and February 2014, respectively, by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate acute pain in adults.
Help employers find you! Check out all the jobs and post your resume.
